Last reviewed · How we verify
iso sorbide dinitrate iv bolus or s/l
Isosorbide dinitrate is a nitrate vasodilator that releases nitric oxide to relax vascular smooth muscle and reduce cardiac preload and afterload.
Isosorbide dinitrate is a nitrate vasodilator that releases nitric oxide to relax vascular smooth muscle and reduce cardiac preload and afterload. Used for Acute angina pectoris (sublingual), Angina prophylaxis (chronic therapy), Acute decompensated heart failure (intravenous).
At a glance
| Generic name | iso sorbide dinitrate iv bolus or s/l |
|---|---|
| Sponsor | Soroka University Medical Center |
| Drug class | Nitrate vasodilator |
| Target | Guanylate cyclase (via nitric oxide) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Isosorbide dinitrate is bioconverted to nitric oxide, which activates guanylate cyclase and increases cGMP levels in vascular smooth muscle cells, causing vasodilation. This reduces venous return (preload) and systemic vascular resistance (afterload), decreasing myocardial oxygen demand and improving coronary blood flow. The drug is used acutely for anginal episodes and chronically for angina prophylaxis and heart failure management.
Approved indications
- Acute angina pectoris (sublingual)
- Angina prophylaxis (chronic therapy)
- Acute decompensated heart failure (intravenous)
Common side effects
- Headache
- Hypotension
- Dizziness
- Tachycardia
- Flushing
- Nitrate tolerance (with chronic use)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: